Laboratorios Farmaceuticos Rovi revenue and financials
€58.95Change from previous close: +1.38%Absolute change: +€0.80
In the fiscal year ended December 2025, Laboratorios Farmaceuticos Rovi reported revenue of €743.48M (−2.65% year over year). Net income was €140.44M, a net margin of 18.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −2.65%
- 2025 vs 2024
- Net income growth
- +2.60%
- 2025 vs 2024
- Net margin
- 18.9%
- 2024: 17.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 192 | 152 | 218 | 210 | 160 | — |
| Cost of revenue | 60.0 | 59.6 | 79.2 | 62.7 | 54.4 | — |
| Gross profit | 132 | 92.9 | 139 | 148 | 105 | — |
| Operating income | 28.7 | 12.1 | 58.5 | 76.3 | 27.9 | — |
| EBIT | 91.3 | 13.1 | 58.4 | 76.5 | 27.5 | — |
| EBITDA | 101 | 21.2 | 66.6 | 83.9 | 34.9 | — |
| Interest expense | 2.0 | 0.8 | 0.5 | 0.8 | 0.7 | — |
| Pre-tax income | 89.3 | 12.3 | 57.9 | 75.7 | 26.8 | — |
| Income tax | 14.4 | 2.8 | 15.3 | 17.7 | 5.2 | — |
| Net income | 75.0 | 9.5 | 42.7 | 58.0 | 21.6 | — |
| Net income to common shareholders | 75.0 | 9.5 | 42.7 | 58.0 | 21.6 | — |
| Basic EPS | — | 0.19 | — | — | — | 0.35 |
| Diluted EPS | — | 0.19 | — | — | — | 0.35 |
| Average shares (basic) | — | 51.1 | — | — | — | 51.1 |
| Average shares (diluted) | — | 51.1 | — | — | — | 51.1 |